1/26/2022 4:55:40 PM
Vertex Pharma Q4 EPS $3.00 Vs. $2.30 Last Year
1/11/2022 3:06:38 AM
Vertex Pharma: EU Approves KAFTRIO In Combination With Ivacaftor For Cystic Fibrosis In Patients Ages 6 Through 11 Years
12/1/2021 7:38:38 AM
Vertex Announces Positive Results From Phase 2 Study Of VX-147 In
APOL1-Mediated FSGS
11/19/2021 6:03:35 AM
Vertex Announces Reimbursement Deal In Spain For KAFTRIO In Combination With Ivacaftor To Treat Cystic Fibrosis
11/12/2021 7:30:27 AM
Vertex Gets CHMP Positive Opinion For KAFTRIO In Combination With Ivacaftor In Children With Cystic Fibrosis
11/2/2021 4:11:55 PM
Vertex Pharma Q3 EPS $3.28 Vs. $2.53 Year Ago
10/19/2021 8:06:57 AM
Vertex To Present Long-Term Data Demonstrating Significant Benefits Of Treatment With CFTR Modulators
10/18/2021 7:34:49 AM
Vertex Announces Positive Day 90 Data In Phase 1/2 Trial Of VX-880 For Type 1 Diabetes